Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etiaxil is a line of over-the-counter (OTC) consumer health products developed and marketed by Cooperation Pharmaceutique Francaise (Laboratoires Cooper) for the treatment of excessive sweating, or hyperhidrosis. The core of the Etiaxil range consists of "detranspirant" formulations where the primary active ingredient is aluminum chloride. When applied topically, aluminum chloride reacts with water and proteins within the sweat duct to form a temporary gel-like plug. This plug physically obstructs the sweat gland, significantly reducing the flow of perspiration to the skin's surface for several days. In addition to its mechanical blocking action, the formulation provides antibacterial properties that help mitigate body odor. The Etiaxil brand encompasses various formats, including roll-ons, sprays, and aerosols, with specific versions designed for sensitive skin and different body areas such as the underarms, hands, and feet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Etiaxil.